Mahalakshimi Yerramilli, Falmouth, ME (US); Michael Randolph Atkinson, Gorham, ME (US); and Murthy V. S. N. Yerramilli, Falmouth, ME (US)
Assigned to IDEXX Laboratories, Inc., Westbrook, ME (US)
Filed by IDEXX LABORATORIES, INC., Westbrook, ME (US)
Filed on Feb. 5, 2024, as Appl. No. 18/432,995.
Application 17/815,765 is a division of application No. 16/571,345, filed on Sep. 16, 2019, granted, now 11,435,365, issued on Sep. 16, 2022.
Application 16/571,345 is a division of application No. 13/700,992, granted, now 10,436,797, issued on Oct. 8, 2019, previously published as PCT/US2011/039122, filed on Jun. 3, 2011.
Application 18/432,995 is a continuation of application No. 17/815,765, filed on Jul. 28, 2022, granted, now 11,933,792.
Claims priority of provisional application 61/411,280, filed on Nov. 8, 2010.
Claims priority of provisional application 61/351,183, filed on Jun. 3, 2010.
Prior Publication US 2024/0230670 A1, Jul. 11, 2024
1. A method for diagnosis and treatment of kidney disease prior to stage 3 of kidney disease comprising detecting the amount of at least one canine Cystatin B polypeptide selected from the group consisting of full length canine Cystatin B, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO: 34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:37, and SEQ ID NO:38 in a canine patient sample; diagnosing the canine patient with kidney disease prior to stage 3 of kidney disease wherein the amount of at least one Cystatin B polypeptide is differentially expressed as compared to a control; and treating the canine patient with (i) dialysis; (ii) a diet low in phosphorous and protein; or (iii) dialysis and a diet low in phosphorous and protein.